Scorpion Therapeutics develops precision oncology therapies that target specific genetic mutations and chromosomal instabilities in cancer cells, enhancing treatment efficacy and safety. By focusing on validated cancer drivers, the company aims to increase the eligibility and clinical benefit of precision therapies for a broader population of cancer patients.
Funding
$420M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FLFounders
Product
Problem
Current precision oncology therapies only benefit a small fraction of cancer patients due to the limited number of successfully targeted cancer drivers. Many patients with cancers driven by specific genetic mutations and chromosomal instabilities lack effective and safe treatment options. This results in a significant unmet need for therapies that can selectively target these validated cancer drivers to improve patient outcomes.
Solution
Scorpion Therapeutics is developing a new generation of precision oncology therapies designed to selectively target validated cancer drivers, including specific genetic mutations and chromosomal instabilities. Their approach aims to improve the safety and efficacy of treatments, increasing the number of patients who can benefit from precision medicine. By focusing on creating drugs that interact with cancer targets with greater selectivity and optimized pharmaceutical properties, Scorpion Therapeutics seeks to deliver more effective and less toxic therapies. Their lead program, STX-478, is a mutant-selective PI3Kα inhibitor in Phase 1/2 clinical trials for breast cancer and other advanced solid tumors, representing a potential next-generation treatment option.
Target Audience
The primary target audience includes patients with cancers driven by specific genetic mutations and chromosomal instabilities, particularly those with PI3Kα mutations in hormone-positive breast cancer and other advanced solid tumors.
Features
- Development of small molecule precision oncology therapies.
- Focus on validated cancer targets with genetic mutations and chromosomal instabilities.
- STX-478: A mutant-selective PI3Kα inhibitor currently in Phase 1/2 clinical trials.
- Designed for improved selectivity and optimized pharmaceutical properties.